SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

SVB Wealth LLC lifted its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 92.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,446,552 shares of the company's stock after acquiring an additional 693,422 shares during the period. 10x Genomics makes up about 2.0% of SVB Wealth LLC's investment portfolio, making the stock its 7th largest holding. SVB Wealth LLC owned about 1.22% of 10x Genomics worth $80,949,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. ARK Investment Management LLC increased its stake in 10x Genomics by 35.0% in the 4th quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company's stock valued at $226,150,000 after buying an additional 1,047,827 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of 10x Genomics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 8,903,517 shares of the company's stock worth $367,270,000 after buying an additional 354,921 shares during the period. TD Asset Management Inc boosted its holdings in shares of 10x Genomics by 72.8% during the 3rd quarter. TD Asset Management Inc now owns 238,364 shares of the company's stock worth $9,833,000 after buying an additional 100,382 shares during the period. RTW Investments LP boosted its holdings in shares of 10x Genomics by 3.9% during the 3rd quarter. RTW Investments LP now owns 1,519,956 shares of the company's stock worth $62,698,000 after buying an additional 57,000 shares during the period. Finally, Primecap Management Co. CA bought a new stake in shares of 10x Genomics during the 3rd quarter worth about $1,242,000. Institutional investors own 84.68% of the company's stock.

Insider Activity

In other news, CEO Serge Saxonov sold 4,660 shares of the company's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $44.00, for a total value of $205,040.00. Following the sale, the chief executive officer now directly owns 842,900 shares of the company's stock, valued at approximately $37,087,600. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Serge Saxonov sold 4,660 shares of the company's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $44.00, for a total value of $205,040.00. Following the sale, the chief executive officer now directly owns 842,900 shares of the company's stock, valued at approximately $37,087,600. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Justin J. Mcanear sold 1,865 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $86,424.10. Following the transaction, the chief financial officer now directly owns 95,240 shares in the company, valued at $4,413,421.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,959 shares of company stock valued at $773,766. 10.65% of the stock is currently owned by insiders.

10x Genomics Price Performance

TXG stock traded down $1.69 during trading on Monday, reaching $32.86. 1,292,153 shares of the company were exchanged, compared to its average volume of 1,401,193. The company has a 50-day moving average of $41.22 and a two-hundred day moving average of $43.28. The company has a market capitalization of $3.92 billion, a price-to-earnings ratio of -15.14 and a beta of 1.90. 10x Genomics, Inc. has a twelve month low of $32.68 and a twelve month high of $63.57.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The business had revenue of $183.98 million during the quarter, compared to analyst estimates of $182.73 million. During the same quarter last year, the company posted ($0.15) earnings per share. The company's revenue was up 17.8% compared to the same quarter last year. On average, analysts forecast that 10x Genomics, Inc. will post -1.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Barclays cut their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, April 10th. Stifel Nicolaus cut their price objective on shares of 10x Genomics from $68.00 to $63.00 and set a "buy" rating for the company in a report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, 10x Genomics has a consensus rating of "Moderate Buy" and an average price target of $60.88.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.